Alpha-1 antitrypsin deficiency: new developments in augmentation and other therapies.

about

Acute-phase protein α1-anti-trypsin: diverting injurious innate and adaptive immune responses from non-authentic threats Mechanistic evidence in support of alpha1-antitrypsin as a therapeutic approach for type 1 diabetes

P2860

Q26858837-2E73AA43-09FD-4375-BE22-AF9580BB68AE Q26861561-616B8773-0C17-4592-8A39-4DC6862390A0

P2860

Alpha-1 antitrypsin deficiency: new developments in augmentation and other therapies.

Item

http://www.wikidata.org/entity/Q38114852

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Alpha-1 antitrypsin deficiency: new developments in augmentation and other therapies.

@en

type

Item

label

Alpha-1 antitrypsin deficiency: new developments in augmentation and other therapies.

@en

prefLabel

Alpha-1 antitrypsin deficiency: new developments in augmentation and other therapies.

@en

P1476

Alpha-1 antitrypsin deficiency: new developments in augmentation and other therapies.

@en

P2860

Grp78, Grp94, and Grp170 interact with alpha1-antitrypsin mutants that are retained in the endoplasmic reticulum

Uromodulin promoter directs high-level expression of biologically active human alpha1-antitrypsin into mouse urine

Targeted gene correction of α1-antitrypsin deficiency in induced pluripotent stem cells

Small molecules block the polymerization of Z alpha1-antitrypsin and increase the clearance of intracellular aggregates

Alpha 1-antitrypsin deficiency. 3: Clinical manifestations and natural history

Alpha-1 antitrypsin deficiency targeted testing and augmentation therapy: a Canadian Thoracic Society clinical practice guideline

High-level expression of biologically active human alpha 1-antitrypsin in the milk of transgenic mice

Pharmacokinetic comparability of Prolastin®-C to Prolastin® in alpha₁-antitrypsin deficiency: a randomized study.

Neutrophils and protease/antiprotease imbalance.

Survival in severe alpha-1-antitrypsin deficiency (PiZZ).

P2888

s40259-013-0042-5

P304

547-558

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S40259-013-0042-5

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Alice M. Turner

P577

2013-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

239076245

http://www.w3.org/2001/XMLSchema#string

P698

23771682

http://www.w3.org/2001/XMLSchema#string

Alpha-1 antitrypsin deficiency: new developments in augmentation and other therapies.

about

P2860

P2860

Alpha-1 antitrypsin deficiency: new developments in augmentation and other therapies.

description

name

type

label

prefLabel

P1433

P1476

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P5875

P698

P356

P1433

P1476

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P5875

P698